Search

Your search keyword '"McVerry, Bryan J"' showing total 525 results
Start Over Author "McVerry, Bryan J"
525 results on '"McVerry, Bryan J"'

2. Longitudinal multicompartment characterization of host-microbiota interactions in patients with acute respiratory failure

Author

Kitsios, Georgios D., Sayed, Khaled, Fitch, Adam, Yang, Haopu, Britton, Noel, Shah, Faraaz, Bain, William, Evankovich, John W., Qin, Shulin, Wang, Xiaohong, Li, Kelvin, Patel, Asha, Zhang, Yingze, Radder, Josiah, Dela Cruz, Charles, Okin, Daniel A., Huang, Ching‐Ying, Van Tyne, Daria, Benos, Panayiotis V., Methé, Barbara, Lai, Peggy, Morris, Alison, and McVerry, Bryan J.

Published
2024
Full Text
View/download PDF

5. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2024
Full Text
View/download PDF

6. Magnetic-activated cell sorting identifies a unique lung microbiome community

Author

Dunlap, Daniel G, Yang, Libing, Qin, Shulin, Li, Kelvin, Fitch, Adam, Huang, Laurence, McVerry, Bryan J, Hand, Timothy W, Methé, Barbara A, and Morris, Alison

Subjects
Microbiology, Biological Sciences, Lung, Infectious Diseases, Genetics, Clinical Research, HIV/AIDS, Prevention, Aetiology, 2.2 Factors relating to the physical environment, Infection, Respiratory, Humans, RNA, Ribosomal, 16S, Microbiota, Immunoglobulin G, Cytokines, Dimercaprol, Magnetic Phenomena, HIV Infections, Microbiome, Immunoglobulin, Host response, Ecology, Medical Microbiology, Evolutionary biology
Abstract

BackgroundThe advent of culture-independent, next-generation DNA sequencing has led to the discovery of distinct lung bacterial communities. Studies of lung microbiome taxonomy often reveal only subtle differences between health and disease, but host recognition and response may distinguish the members of similar bacterial communities in different populations. Magnetic-activated cell sorting has been applied to the gut microbiome to identify the numbers and types of bacteria eliciting a humoral response. We adapted this technique to examine the populations of immunoglobulin-bound bacteria in the lung.MethodsSixty-four individuals underwent bronchoalveolar lavage (BAL). We separated immunoglobulin G-bound bacteria using magnetic-activated cell sorting and sequenced the 16S rRNA gene on the Illumina MiSeq platform. We compared microbial sequencing data in IgG-bound bacterial communities compared to raw BAL then examined the differences in individuals with and without HIV as a representative disease state.ResultsImmunoglobulin G-bound bacteria were identified in all individuals. The community structure differed when compared to raw BAL, and there was a greater abundance of Pseudomonas and fewer oral bacteria in IgG-bound BAL. Examination of IgG-bound communities in individuals with HIV demonstrated the differences in Ig-bound bacteria by HIV status that were not seen in a comparison of raw BAL, and greater numbers of immunoglobulin-bound bacteria were associated with higher pulmonary cytokine levels.ConclusionsWe report a novel application of magnetic-activated cell sorting to identify immunoglobulin G-bound bacteria in the lung. This technique identified distinct bacterial communities which differed in composition from raw bronchoalveolar lavage, revealing the differences not detected by traditional analyses. Cytokine response was also associated with differential immunoglobulin binding of lung bacteria, suggesting the functional importance of these communities. Video Abstract.

Published
2023

8. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

Author

Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, and Lawler, Patrick R.

Published
2024
Full Text
View/download PDF

9. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Author

Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, Kutcher, Matthew E, Laffan, Michael A, Lamontagne, Francois, and Le Gal, Grégoire

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Comparative Effectiveness Research, Cardiovascular, Good Health and Well Being, Aged, Anticoagulants, COVID-19, Critical Illness, Female, Hemorrhage, Heparin, Hospital Mortality, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Respiration, Artificial, Thrombosis, Treatment Failure, COVID-19 Drug Treatment, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

10. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Author

Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Krishnan, Vidya

Subjects
Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Transplantation, Good Health and Well Being, Adult, Aged, Anticoagulants, COVID-19, Female, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Hospital Mortality, Humans, Male, Middle Aged, Survival Analysis, Thrombosis, COVID-19 Drug Treatment, ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

11. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Author

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Knudson, M Margaret, Kornblith, Aaron E, and Kutcher, Matthew E

Subjects
REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Humans, Thrombosis, Critical Illness, Hemorrhage, Heparin, Anticoagulants, Treatment Failure, Respiration, Artificial, Hospital Mortality, Logistic Models, Odds Ratio, Aged, Middle Aged, Female, Male, COVID-19, Clinical Research, Cardiovascular, Clinical Trials and Supportive Activities, Comparative Effectiveness Research, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.MethodsIn an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge.ResultsThe trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio

Published
2021

12. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

Author

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, Patrick R, Goligher, Ewan C, Berger, Jeffrey S, Neal, Matthew D, McVerry, Bryan J, Nicolau, Jose C, Gong, Michelle N, Carrier, Marc, Rosenson, Robert S, Reynolds, Harmony R, Turgeon, Alexis F, Escobedo, Jorge, Huang, David T, Bradbury, Charlotte A, Houston, Brett L, Kornblith, Lucy Z, Kumar, Anand, Kahn, Susan R, Cushman, Mary, McQuilten, Zoe, Slutsky, Arthur S, Kim, Keri S, Gordon, Anthony C, Kirwan, Bridget-Anne, Brooks, Maria M, Higgins, Alisa M, Lewis, Roger J, Lorenzi, Elizabeth, Berry, Scott M, Berry, Lindsay R, Aday, Aaron W, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Baumann Kreuziger, Lisa, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Costantini, Todd W, de Brouwer, Sophie, Derde, Lennie PG, Detry, Michelle A, Duggal, Abhijit, Džavík, Vladimír, Effron, Mark B, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, García-Madrona, Sebastian, Girard, Timothy D, Godoy, Lucas C, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Hamburg, Naomi M, Haniffa, Rashan, Hanna, George, Hanna, Nicholas, Hegde, Sheila M, Hendrickson, Carolyn M, Hite, R Duncan, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Iyer, Vivek N, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei L, and King, Andrew J

Subjects
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Humans, Thrombosis, Hemorrhage, Heparin, Heparin, Low-Molecular-Weight, Anticoagulants, Hospital Mortality, Survival Analysis, Adult, Aged, Middle Aged, Female, Male, COVID-19, Hematology, Clinical Trials and Supportive Activities, Transplantation, Clinical Research, Cardiovascular, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundThrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.MethodsIn this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.ResultsThe trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.ConclusionsIn noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).

Published
2021

13. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Author

Arabi, Yaseen M, Gordon, Anthony C, Derde, Lennie PG, Nichol, Alistair D, Murthy, Srinivas, Beidh, Farah Al, Annane, Djillali, Swaidan, Lolowa Al, Beane, Abi, Beasley, Richard, Berry, Lindsay R, Bhimani, Zahra, Bonten, Marc JM, Bradbury, Charlotte A, Brunkhorst, Frank M, Buxton, Meredith, Buzgau, Adrian, Cheng, Allen, De Jong, Menno, Detry, Michelle A, Duffy, Eamon J, Estcourt, Lise J, Fitzgerald, Mark, Fowler, Rob, Girard, Timothy D, Goligher, Ewan C, Goossens, Herman, Haniffa, Rashan, Higgins, Alisa M, Hills, Thomas E, Horvat, Christopher M, Huang, David T, King, Andrew J, Lamontagne, Francois, Lawler, Patrick R, Lewis, Roger, Linstrum, Kelsey, Litton, Edward, Lorenzi, Elizabeth, Malakouti, Salim, McAuley, Daniel F, McGlothlin, Anna, Mcguinness, Shay, McVerry, Bryan J, Montgomery, Stephanie K, Morpeth, Susan C, Mouncey, Paul R, Orr, Katrina, Parke, Rachael, Parker, Jane C, Patanwala, Asad E, Rowan, Kathryn M, Santos, Marlene S, Saunders, Christina T, Seymour, Christopher W, Shankar-Hari, Manu, Tong, Steven YC, Turgeon, Alexis F, Turner, Anne M, Van de Veerdonk, Frank Leo, Zarychanski, Ryan, Green, Cameron, Berry, Scott, Marshall, John C, McArthur, Colin, Angus, Derek C, and Webb, Steven A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Comparative Effectiveness Research, Clinical Research, Clinical Trials and Supportive Activities, Good Health and Well Being, Adult, Antiviral Agents, Bayes Theorem, Critical Illness, Drug Combinations, Humans, Hydroxychloroquine, Lopinavir, Ritonavir, SARS-CoV-2, COVID-19 Drug Treatment, Adaptive platform trial, Intensive care, Pneumonia, Pandemic, COVID-19, Lopinavir-ritonavir, REMAP-CAP Investigators, Public Health and Health Services, Emergency & Critical Care Medicine, Clinical sciences
Abstract

PurposeTo study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).MethodsCritically ill adults with COVID-19 were randomized to receive lopinavir-ritonavir, hydroxychloroquine, combination therapy of lopinavir-ritonavir and hydroxychloroquine or no antiviral therapy (control). The primary endpoint was an ordinal scale of organ support-free days. Analyses used a Bayesian cumulative logistic model and expressed treatment effects as an adjusted odds ratio (OR) where an OR > 1 is favorable.ResultsWe randomized 694 patients to receive lopinavir-ritonavir (n = 255), hydroxychloroquine (n = 50), combination therapy (n = 27) or control (n = 362). The median organ support-free days among patients in lopinavir-ritonavir, hydroxychloroquine, and combination therapy groups was 4 (- 1 to 15), 0 (- 1 to 9) and-1 (- 1 to 7), respectively, compared to 6 (- 1 to 16) in the control group with in-hospital mortality of 88/249 (35%), 17/49 (35%), 13/26 (50%), respectively, compared to 106/353 (30%) in the control group. The three interventions decreased organ support-free days compared to control (OR [95% credible interval]: 0.73 [0.55, 0.99], 0.57 [0.35, 0.83] 0.41 [0.24, 0.72]), yielding posterior probabilities that reached the threshold futility (≥ 99.0%), and high probabilities of harm (98.0%, 99.9% and > 99.9%, respectively). The three interventions reduced hospital survival compared with control (OR [95% CrI]: 0.65 [0.45, 0.95], 0.56 [0.30, 0.89], and 0.36 [0.17, 0.73]), yielding high probabilities of harm (98.5% and 99.4% and 99.8%, respectively).ConclusionAmong critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy.

Published
2021

15. Trajectories of Host-Response Subphenotypes in Patients With COVID-19 Across the Spectrum of Respiratory Support

Author

Lu, Michael, Drohan, Callie, Bain, William, Shah, Faraaz A., Bittner, Matthew, Evankovich, John, Prendergast, Niall T., Hensley, Matthew, Suber, Tomeka L., Fitzpatrick, Meghan, Ramanan, Raj, Murray, Holt, Schaefer, Caitlin, Qin, Shulin, Wang, Xiaohong, Zhang, Yingze, Nouraie, Seyed M., Gentry, Heather, Murray, Cathy, Patel, Asha, Macatangay, Bernard J., Jacobs, Jana, Mellors, John W., Lee, Janet S., Ray, Prabir, Ray, Anuradha, Methé, Barbara, Morris, Alison, McVerry, Bryan J., and Kitsios, Georgios D.

Published
2023
Full Text
View/download PDF

17. Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA

Author

Lisius, Grace, Duttagupta, Radha, Ahmed, Asim A., Hensley, Matthew, Al-Yousif, Nameer, Lu, Michael, Bain, William, Shah, Faraaz, Blauwkamp, Timothy A., Bercovici, Sivan, Schaefer, Caitlin, Qin, Shulin, Wang, Xiaohong, Zhang, Yingze, Mitchell, Kevin J., Hughes, Ellen K., Jacobs, Jana L., Naqvi, Asma, Haidar, Ghady, Mellors, John W., Methé, Barbara, McVerry, Bryan J., Morris, Alison, and Kitsios, Georgios D.

Published
2023
Full Text
View/download PDF

18. Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial

Author

Smilowitz, Nathaniel R., Hade, Erinn M., Kornblith, Lucy Z., Castellucci, Lana A., Cushman, Mary, Farkouh, Michael, Gong, Michelle N., Heath, Anna, Hunt, Beverly J., Kim, Keri S., Kindzelski, Andrei, Lawler, Patrick, Leaf, David E., Goligher, Ewan, Leifer, Eric S., McVerry, Bryan J., Reynolds, Harmony R., Zarychanski, Ryan, Hochman, Judith S., Neal, Matthew D., and Berger, Jeffrey S.

Published
2023
Full Text
View/download PDF

19. The upper and lower respiratory tract microbiome in severe aspiration pneumonia

Author

Kitsios, Georgios D., Nguyen, Vi D., Sayed, Khaled, Al-Yousif, Nameer, Schaefer, Caitlin, Shah, Faraaz A., Bain, William, Yang, Haopu, Fitch, Adam, Li, Kelvin, Wang, Xiaohong, Qin, Shulin, Gentry, Heather, Zhang, Yingze, Varon, Jack, Arciniegas Rubio, Antonio, Englert, Joshua A., Baron, Rebecca M., Lee, Janet S., Methé, Barbara, Benos, Panayiotis V., Morris, Alison, and McVerry, Bryan J.

Published
2023
Full Text
View/download PDF

20. The Microbiome in Acute Lung Injury and ARDS

Author

Kitsios, Georgios D., Franz, Christopher, McVerry, Bryan J., Rounds, Sharon I. S., Series Editor, Dixon, Anne, Series Editor, Schnapp, Lynn M., Series Editor, Huang, Yvonne J., editor, and Garantziotis, Stavros, editor

Published
2022
Full Text
View/download PDF

21. Abstract 13200: Changes in Thrombi-Inflammatory Biomarkers Associated With Therapeutic Heparin in Non-Critically Ill Patients Hospitalized With COVID-19: A Pre-Specified Secondary Analysis of the ACTIV4a and ATTACC Randomized Clinical Trial

Author

Wahid, Lana, Froess, Joshua, Ortel, Thomas L, Zarychanski, Ryan, Gong, Michelle N, Cushman, Mary, Kornblith, Lucy, Castellucci, Lana, Farkouh, Michael E, Gologher, Ewan, McVerry, Bryan J, Bochicchio, Grant V, Duggal, Abhijit, Greenstein, Yonatan, Hanna, Nicholas, Hudock, Kristin, Huang, David T, Hyzy, Robert, Khan, Akram, Krishnan, Vidya, Kutcher, Matthew, Lim, George, Lopez-Sendon Moreno, Jose Luis, Matthay, Michael A, Pandey, Ambarish, Quigley, John, Satterwhite, Lewis, Widmer, Robert J, Jenny Wilson, Jenny, Hochman, Judith S, Berger, Jeffrey S, Neal, Matthew D, and Lawler, Patrick R

Published
2023
Full Text
View/download PDF

22. A common single nucleotide polymorphism is associated with inflammation and critical illness outcomes

Author

El-Dehaibi, Fayten, primary, Zamora, Ruben, additional, Radder, Josiah, additional, Yin, Jinling, additional, Shah, Ashti M., additional, Namas, Rami A., additional, Situ, Michelle, additional, Zhao, Yanwu, additional, Bain, William, additional, Morris, Alison, additional, McVerry, Bryan J., additional, Barclay, Derek A., additional, Billiar, Timothy R., additional, Zhang, Yingze, additional, Kitsios, Georgios D., additional, and Vodovotz, Yoram, additional

Published
2024
Full Text
View/download PDF

23. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Author

Matthay, Michael A, Calfee, Carolyn S, Zhuo, Hanjing, Thompson, B Taylor, Wilson, Jennifer G, Levitt, Joseph E, Rogers, Angela J, Gotts, Jeffrey E, Wiener-Kronish, Jeanine P, Bajwa, Ednan K, Donahoe, Michael P, McVerry, Bryan J, Ortiz, Luis A, Exline, Matthew, Christman, John W, Abbott, Jason, Delucchi, Kevin L, Caballero, Lizette, McMillan, Melanie, McKenna, David H, and Liu, Kathleen D

Subjects
Humans, Disease-Free Survival, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Severity of Illness Index, Hospital Mortality, Multivariate Analysis, Proportional Hazards Models, Risk Assessment, Statistics, Nonparametric, Survival Analysis, Prospective Studies, Double-Blind Method, Adult, Aged, Middle Aged, Academic Medical Centers, United States, Female, Male, Patient Safety, Respiratory Distress Syndrome, Rare Diseases, Stem Cell Research, Acute Respiratory Distress Syndrome, Stem Cell Research - Nonembryonic - Human, Clinical Trials and Supportive Activities, Clinical Research, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Respiratory, Good Health and Well Being, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

BackgroundTreatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety has not been established for administration of MSCs in critically ill patients with ARDS. We did a phase 2a trial to assess safety after administration of MSCs to patients with moderate to severe ARDS.MethodsWe did a prospective, double-blind, multicentre, randomised trial to assess treatment with one intravenous dose of MSCs compared with placebo. We recruited ventilated patients with moderate to severe ARDS (ratio of partial pressure of oxygen to fractional inspired oxygen

Published
2019

24. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial

Author

McCreary, Erin K., Bariola, J. Ryan, Minnier, Tami E., Wadas, Richard J., Shovel, Judith A., Albin, Debbie, Marroquin, Oscar C., Kip, Kevin E., Collins, Kevin, Schmidhofer, Mark, Wisniewski, Mary Kay, Nace, David A., Sullivan, Colleen, Axe, Meredith, Meyers, Russell, Weissman, Alexandra, Garrard, William, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert D., Yang, Anne, Berry, Lindsay R., Berry, Scott, Crawford, Amy M., McGlothlin, Anna, Khadem, Tina, Linstrum, Kelsey, Montgomery, Stephanie K., Ricketts, Daniel, Kennedy, Jason N., Pidro, Caroline J., Haidar, Ghady, Snyder, Graham M., McVerry, Bryan J., Yealy, Donald M., Angus, Derek C., Nakayama, Anna, Zapf, Rachel L., Kip, Paula L., Seymour, Christopher W., and Huang, David T.

Published
2022
Full Text
View/download PDF

26. Inflammatory Subphenotype Is Associated with Acute Brain Dysfunction in Mechanically Ventilated Patients.

Author

Prendergast, Niall T., Franz, Christopher A., Schaefer, Caitlin, Covell, Nicole Bensen, Balish, Kelsey, Onyemekwu, Chukwudi A., Potter, Kelly M., Zhang, Yingze, Bain, William G., Shah, Faraaz A., Nouraie, S. Mehdi, McVerry, Bryan J., Kitsios, Georgios D., and Girard, Timothy D.

Subjects
LUNGS, ADULT respiratory distress syndrome
Abstract

The article presents a study which tested the hypothesis that the hyperinflammatory subphenotype is associated with worse acute brain dysfunction in patients who are in mechanically ventilated intensive care units (ICUs). Topics include baseline characteristics of the overall cohort and by subphenotype, associations between hyperinflammatory subphenotype and acute brain dysfunction and death, and strengths of the study.

Published
2024
Full Text
View/download PDF

28. Author Correction 2024: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials(Nature Communications, (2021), 12, (1), 10.1038/s41467-021-22446-z)

Author

Medische Staf Intensive Care, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, MS Interne Geneeskunde, MS Dermatologie/Allergologie, MS Infectieziekten, Axfors, Cathrine, Schmitt, Andreas M, Janiaud, Perrine, Van't Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F, Abella, Benjamin S, Akram, Javed, Amaravadi, Ravi K, Angus, Derek C, Arabi, Yaseen M, Azhar, Shehnoor, Baden, Lindsey R, Baker, Arthur W, Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A H, Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z, Cowan, Lisa N, Dalgard, Olav, de Almeida E Val, Fernando F, de Lacerda, Marcus V G, de Melo, Gisely C, Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C, Hernandez-Cardenas, Carmen M, Hills, Thomas, Hoepelman, Andy I M, Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S, Kremsner, Peter G, Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J, Meza-Meneses, Patricia, Monteiro, Wuelton M, Morpeth, Susan C, Mourad, Ahmad, Mulligan, Mark J, Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A, O'Brien, Sean M, Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E, Rockhold, Frank W, Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S, Seto, Todd B, Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E, Thirion-Romero, Ireri, Troxel, Andrea B, Tseng, Ting-Yu, Turner, Nicholas A, Ulrich, Robert J, Walsh, Stephen R, Webb, Steve A, Weehuizen, Jesper M, Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G, Zhong, Wu, Moher, David, Goodman, Steven N, Ioannidis, John P A, Hemkens, Lars G, Medische Staf Intensive Care, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, MS Interne Geneeskunde, MS Dermatologie/Allergologie, MS Infectieziekten, Axfors, Cathrine, Schmitt, Andreas M, Janiaud, Perrine, Van't Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F, Abella, Benjamin S, Akram, Javed, Amaravadi, Ravi K, Angus, Derek C, Arabi, Yaseen M, Azhar, Shehnoor, Baden, Lindsey R, Baker, Arthur W, Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A H, Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z, Cowan, Lisa N, Dalgard, Olav, de Almeida E Val, Fernando F, de Lacerda, Marcus V G, de Melo, Gisely C, Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C, Hernandez-Cardenas, Carmen M, Hills, Thomas, Hoepelman, Andy I M, Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S, Kremsner, Peter G, Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J, Meza-Meneses, Patricia, Monteiro, Wuelton M, Morpeth, Susan C, Mourad, Ahmad, Mulligan, Mark J, Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A, O'Brien, Sean M, Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E, Rockhold, Frank W, Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S, Seto, Todd B, Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E, Thirion-Romero, Ireri, Troxel, Andrea B, Tseng, Ting-Yu, Turner, Nicholas A, Ulrich, Robert J, Walsh, Stephen R, Webb, Steve A, Weehuizen, Jesper M, Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G, Zhong, Wu, Moher, David, Goodman, Steven N, Ioannidis, John P A, and Hemkens, Lars G

Published
2024

29. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

Author

Medische Staf Intensive Care, Infection & Immunity, Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, Lawler, Patrick R., Medische Staf Intensive Care, Infection & Immunity, Godoy, Lucas C., Neal, Matthew D., Goligher, Ewan C., Cushman, Mary, Houston, Brett L., Bradbury, Charlotte A., McQuilten, Zoe K., Tritschler, Tobias, Kahn, Susan R., Berry, Lindsay R., Lorenzi, Elizabeth, Jensen, Tom, Higgins, Alisa M., Kornblith, Lucy Z., Berger, Jeffrey S., Gong, Michelle N., Paul, Jonathan D., Castellucci, Lana A., Le Gal, Grégoire, Lother, Sylvain A., Rosenson, Robert S., Derde, Lennie P.G., Kumar, Anand, McVerry, Bryan J., Nicolau, Jose C., Leifer, Eric, Escobedo, Jorge, Huang, David T., Reynolds, Harmony R., Carrier, Marc, Kim, Keri S., Hunt, Beverley J., Slutsky, Arthur S., Turgeon, Alexis F., Webb, Steven A., McArthur, Colin J., Farkouh, Michael E., Hochman, Judith S., Zarychanski, Ryan, and Lawler, Patrick R.

Published
2024

30. Abstract 14850: Effect of Therapeutic-Dose Heparin on Acute Kidney Injury in Non-Critically Ill Hospitalized Patients With Covid-19: The Activ4a and Attac Randomized Trial

Author

Smilowitz, Nathaniel, Hade, Erinn, Kornblith, Lucy, Castellucci, Lana, Cushman, Mary, Farkouh, Michael E, Hunt, Beverly, Kim, Keri, Kindzelski, Andrei, Lawler, Patrick R, Leifer, Eric, McVerry, Bryan J, Reynolds, Harmony, Hochman, Judith, Hochman, Judith S, Neal, Matthew D, and Berger, Jeffrey S

Published
2022
Full Text
View/download PDF

32. Lung Epithelium Releases Growth Differentiation Factor 15 in Response to Pathogen-mediated Injury

Author

Shah, Faraaz A., primary, Bahudhanapati, Harinath, additional, Jiang, Mao, additional, Tabary, Mohammadreza, additional, van der Geest, Rick, additional, Tolman, Nathanial J., additional, Kochin, Megan, additional, Xiong, Zeyu, additional, Al-Yousif, Nameer, additional, Sayed, Khaled, additional, Benos, Panayiotis V, additional, Raffensperger, Kristen, additional, Evankovich, John, additional, Neal, Matthew D, additional, Snyder, Mark E., additional, Eickelberg, Oliver, additional, Ray, Prabir, additional, Dela Cruz, Charles, additional, Bon, Jessica, additional, McVerry, Bryan J., additional, Straub, Adam C., additional, Jurczak, Michael J., additional, Suber, Tomeka I., additional, Zhang, Yingze, additional, Chen, Kong, additional, Kitsios, Georgios D., additional, Lee, Janet S., additional, Alder, Jonathan K, additional, and Bain, William G., additional

Published
2024
Full Text
View/download PDF

33. Lung microvascular occlusion by platelet-rich neutrophil-platelet aggregates promotes cigarette smoke–induced severe flu

Author

Kaminski, Tomasz W., primary, Brzoska, Tomasz, additional, Li, Xiuying, additional, Vats, Ravi, additional, Katoch, Omika, additional, Dubey, Rikesh K., additional, Bagale, Kamal, additional, Watkins, Simon C., additional, McVerry, Bryan J., additional, Pradhan-Sundd, Tirthadipa, additional, Zhang, Lianghui, additional, Robinson, Keven M., additional, Nyunoya, Toru, additional, and Sundd, Prithu, additional

Published
2024
Full Text
View/download PDF

35. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

36. Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

38. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Author

Axfors, Cathrine, Schmitt, Andreas M., Janiaud, Perrine, van’t Hooft, Janneke, Abd-Elsalam, Sherief, Abdo, Ehab F., Abella, Benjamin S., Akram, Javed, Amaravadi, Ravi K., Angus, Derek C., Arabi, Yaseen M., Azhar, Shehnoor, Baden, Lindsey R., Baker, Arthur W., Belkhir, Leila, Benfield, Thomas, Berrevoets, Marvin A. H., Chen, Cheng-Pin, Chen, Tsung-Chia, Cheng, Shu-Hsing, Cheng, Chien-Yu, Chung, Wei-Sheng, Cohen, Yehuda Z., Cowan, Lisa N., Dalgard, Olav, de Almeida e Val, Fernando F., de Lacerda, Marcus V. G., de Melo, Gisely C., Derde, Lennie, Dubee, Vincent, Elfakir, Anissa, Gordon, Anthony C., Hernandez-Cardenas, Carmen M., Hills, Thomas, Hoepelman, Andy I. M., Huang, Yi-Wen, Igau, Bruno, Jin, Ronghua, Jurado-Camacho, Felipe, Khan, Khalid S., Kremsner, Peter G., Kreuels, Benno, Kuo, Cheng-Yu, Le, Thuy, Lin, Yi-Chun, Lin, Wu-Pu, Lin, Tse-Hung, Lyngbakken, Magnus Nakrem, McArthur, Colin, McVerry, Bryan J., Meza-Meneses, Patricia, Monteiro, Wuelton M., Morpeth, Susan C., Mourad, Ahmad, Mulligan, Mark J., Murthy, Srinivas, Naggie, Susanna, Narayanasamy, Shanti, Nichol, Alistair, Novack, Lewis A., O’Brien, Sean M., Okeke, Nwora Lance, Perez, Léna, Perez-Padilla, Rogelio, Perrin, Laurent, Remigio-Luna, Arantxa, Rivera-Martinez, Norma E., Rockhold, Frank W., Rodriguez-Llamazares, Sebastian, Rolfe, Robert, Rosa, Rossana, Røsjø, Helge, Sampaio, Vanderson S., Seto, Todd B., Shahzad, Muhammad, Soliman, Shaimaa, Stout, Jason E., Thirion-Romero, Ireri, Troxel, Andrea B., Tseng, Ting-Yu, Turner, Nicholas A., Ulrich, Robert J., Walsh, Stephen R., Webb, Steve A., Weehuizen, Jesper M., Velinova, Maria, Wong, Hon-Lai, Wrenn, Rebekah, Zampieri, Fernando G., Zhong, Wu, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

39. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

Author

Huang, David T., McCreary, Erin K., Bariola, J. Ryan, Wadas, Richard J., Kip, Kevin E., Marroquin, Oscar C., Koscumb, Stephen, Collins, Kevin, Shovel, Judith A., Schmidhofer, Mark, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M., Axe, Meredith, Nace, David A., Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Snyder, Graham M., Seymour, Christopher W., Montgomery, Stephanie K., McVerry, Bryan J., Berry, Lindsay, Berry, Scott, Meyers, Russell, Weissman, Alexandra, Peck-Palmer, Octavia M., Wells, Alan, Bart, Robert, Albin, Debbie L., Minnier, Tami, and Angus, Derek C.

Published
2021
Full Text
View/download PDF

40. Surfactant Protein D Influences Mortality During Abdominal Sepsis by Facilitating Escherichia coli Colonization in the Gut

Author

Varon, Jack, Arciniegas Rubio, Antonio, Amador-Munoz, Diana, Corcoran, Alexis, DeCorte, Joseph A., Isabelle, Colleen, Pinilla Vera, Miguel, Walker, Katherine, Brown, Luke, Cernadas, Manuela, Bry, Lynn, Yang, Haopu, Kitsios, Georgios D., McVerry, Bryan J., Morris, Alison, Lee, Hyunwook, Howrylak, Judie, Englert, Joshua A., and Baron, Rebecca M.

Published
2022
Full Text
View/download PDF

44. Stewardship-guided T2Candida testing shortens time to antifungal treatment and reduces antifungal usage among medical ICU patients with septic shock

Author

O’Donnell, Matt, primary, Shields, Ryan K, additional, Marini, Rachel V, additional, Groetzinger, Lara M, additional, Potoski, Brian A, additional, Falcione, Bonnie A, additional, Shah, Sunish, additional, McCreary, Erin K, additional, Clarke, Lloyd, additional, Brant, Emily, additional, McVerry, Bryan J, additional, Liegey, Susan, additional, Pasculle, A William, additional, Clancy, Cornelius J, additional, and Nguyen, M Hong, additional

Published
2023
Full Text
View/download PDF

45. Automatic Population of the Case Report Forms for an International Multifactorial Adaptive Platform Trial Amid the COVID-19 Pandemic

Author

King, Andrew J, primary, Higgins, Lisa, additional, Au, Carly, additional, Malakouti, Salim, additional, Music, Edvin, additional, Kalchthaler, Kyle, additional, Clermont, Gilles, additional, Garrard, William, additional, Huang, David T, additional, McVerry, Bryan J, additional, Seymour, Christopher W, additional, Linstrum, Kelsey, additional, McNamara, Amanda, additional, Green, Cameron, additional, Loar, India D, additional, Roberts, Tracey, additional, Marroquin, Oscar, additional, Angus, Derek C, additional, and Horvat, Christopher M, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results